US 11,746,330 B2
Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
Andrew F. Stewart, New York, NY (US); Courtney Ackeifi, New York, NY (US); Peng Wang, New York, NY (US); and Bob Devita, New York, NY (US)
Assigned to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY (US)
Appl. No. 16/959,390
Filed by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY (US)
PCT Filed Jan. 5, 2019, PCT No. PCT/US2019/012442
§ 371(c)(1), (2) Date Jun. 30, 2020,
PCT Pub. No. WO2019/136320, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/614,136, filed on Jan. 5, 2018.
Prior Publication US 2021/0032601 A1, Feb. 4, 2021
Int. Cl. C12N 5/00 (2006.01); C12N 5/071 (2010.01); A61P 5/48 (2006.01); A61P 3/10 (2006.01); A61K 31/437 (2006.01); A61K 38/22 (2006.01)
CPC C12N 5/0676 (2013.01) [A61K 31/437 (2013.01); A61K 38/22 (2013.01); A61P 3/10 (2018.01); A61P 5/48 (2018.01); C12N 2501/335 (2013.01); C12N 2501/727 (2013.01)] 13 Claims
 
1. A method of increasing cell proliferation in a population of human pancreatic beta cells, said method comprising:
contacting a population of human pancreatic beta cells with a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and a glucagon-like peptide-1 receptor (GLP1R) agonist, wherein said contacting is carried out under conditions effective to cause a synergistic increase in cell proliferation in the population of human pancreatic beta cells.